Providing more bone-strengthening power, the recent FDA approval of a new dual-acting drug is giving patients with osteoporosis more control in preventing additional fractures.
Expanding the approval of a minimally invasive valve repair device to a population of patients who have failed to get symptom relief from other therapies provides an important new treatment option.
Following Fast-Track and Breakthrough designations in 2017 and 2018, 2019 marked the FDA approval of tafamidis, the first-ever medication for treatment of this increasingly recognized condition.
Development of a new oral immunotherapy medication to gradually build tolerance to peanut exposure holds the opportunity to lend protection against attack.
Closed-loop stimulation is allowing for better communication between the device and the spinal cord providing more optimal stimulation and relief of pain.
Biologics – cells, blood components, growth factors, and other natural substances – are finding their way into orthopaedic care, allowing for the possibility of expedited improved outcomes.
Antibiotic-embedded envelopes are now made to encase implantable cardiac electronic devices, effectively preventing infection.
SGLT2 inhibitors, a class of medications used in the treatment of type 2 diabetes, is now being explored in HFpEF – alluding to a potential new treatment option.
Depending on its stage, a diagnosis of ovarian cancer could be the worst news a woman may ever hear.
Heart failure with preserved ejection fraction (HFpEF) – also known as diastolic heart failure – occurs when the heart muscles contract normally, but the left ventricle muscles are thickened.